colitis
Information
- Disease name
- colitis
- Disease ID
- DOID:0060180
- Description
- "An inflammatory bowel disease that involves inflammation located_in colon." [url:http\://en.wikipedia.org/wiki/Colitis]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01326013 | Completed | A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel | June 2011 | March 2012 | |
| NCT00002273 | Completed | N/A | A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS | ||
| NCT00072943 | Completed | Phase 2 | A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease | March 2002 | April 2004 |
| NCT00272818 | Completed | Study to Identify Non-Invasive Markers of Gastrointestinal Allergy | September 2004 | December 2008 | |
| NCT00325013 | Completed | Phase 1 | Evaluation of DHA for the Treatment of PSC | December 2005 | May 2012 |
| NCT00518349 | Completed | N/A | Colonoscope Passive Bending Function | August 2003 | December 2009 |
| NCT00533078 | Completed | Phase 2 | Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies | November 2007 | December 2009 |
| NCT00000768 | Completed | Phase 1 | A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients | August 1998 | |
| NCT01369329 | Completed | Phase 3 | A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) | July 2011 | July 2013 |
| NCT01369342 | Completed | Phase 3 | A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2) | July 2011 | October 2014 |
| NCT01369355 | Completed | Phase 3 | A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) | September 13, 2011 | October 1, 2019 |
| NCT02063282 | Completed | The Risk for Clostridium Difficile Colitis During Hospitalization in Asymptomatic Carriers | February 2014 | December 2014 | |
| NCT02503514 | Completed | Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort | August 2015 | August 2017 | |
| NCT02569333 | Completed | N/A | Patient Centered Algorithms to Optimize the Inpatient Experience and Treatment of Ulcerative Colitis | January 2016 | January 2020 |
| NCT02600143 | Completed | Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy. | August 2013 | April 2019 | |
| NCT02647866 | Completed | Phase 2 | Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis | June 2016 | October 2018 |
| NCT02709213 | Completed | Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Colonoscopy | November 2016 | December 2019 | |
| NCT03378167 | Completed | Phase 1 | PediCRaFT: Pediatric Crohn's Disease Fecal Transplant Trial | December 1, 2018 | September 30, 2023 |
| NCT03601611 | Completed | N/A | Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms | January 1, 2019 | January 28, 2020 |
| NCT05414552 | Completed | ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment | June 1, 2021 | December 30, 2022 | |
| NCT05514561 | Completed | FIT and Fecal Calprotectin in Patients With Chronic Lower GI Symptoms | March 22, 2020 | November 1, 2022 | |
| NCT06074874 | Completed | Intestinal Biomarker Analysis After ECP for ICI Colitis | July 1, 2023 | March 30, 2024 | |
| NCT05918562 | Enrolling by invitation | N/A | Efficacy of a Low Fiber Diet for Pediatric Colonoscopy Prep | April 20, 2021 | September 1, 2023 |
| NCT06424769 | Not yet recruiting | N/A | Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management | May 2024 | September 2028 |
| NCT05726396 | Not yet recruiting | Phase 2 | A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis | June 1, 2024 | December 1, 2024 |
| NCT06223347 | Recruiting | Improved and Simplified Staining Technique for Dysplasia Detection in Colitis | January 2024 | April 2026 | |
| NCT06206707 | Recruiting | N/A | FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis | January 23, 2024 | March 31, 2025 |
| NCT05947669 | Recruiting | Phase 3 | Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis | August 22, 2023 | September 2028 |
| NCT04038619 | Recruiting | Phase 1 | Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | February 1, 2021 | December 31, 2025 |
| NCT03819296 | Recruiting | Phase 1/Phase 2 | Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer | February 21, 2021 | October 31, 2025 |
| NCT05333978 | Recruiting | N/A | Optoacoustic Detection of Inflammation Using MSOT Device | May 31, 2022 | December 31, 2024 |
| NCT04407247 | Recruiting | Phase 1/Phase 2 | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | July 9, 2020 | December 31, 2024 |
| NCT00184171 | Terminated | N/A | Treatment of Microscopic Colitis | November 2001 | October 2014 |
| NCT00936585 | Terminated | N/A | NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease | July 2009 | February 2011 |
| NCT01346059 | Terminated | N/A | Intracolonic Vancomycin Therapy in Severe C. Diff Colitis | April 2011 | February 2012 |
| NCT02333526 | Unknown status | Syndecan 1 as Biomarker for Inflammation | December 2019 | July 2020 | |
| NCT04272307 | Unknown status | MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach. | May 14, 2020 | February 2022 | |
| NCT02768038 | Unknown status | Intestinal Microbiome and Chronic Inflammatory Bowel Disease | May 2016 | December 2020 | |
| NCT02687724 | Unknown status | Phase 4 | Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis | June 2016 | February 2020 |
| NCT03014284 | Withdrawn | Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon Cancer and Treat Colitis | January 20, 2017 | September 12, 2018 | |
| NCT00514982 | Withdrawn | Phase 2 | Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome | August 7, 2007 | March 8, 2011 |
- Disase is a (Disease Ontology)
- DOID:0050589
- Cross Reference ID (Disease Ontology)
- EFO:0003872
- Cross Reference ID (Disease Ontology)
- ICD10CM:K52.9
- Cross Reference ID (Disease Ontology)
- MESH:D003092
- Cross Reference ID (Disease Ontology)
- NCI:C26723
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:64226004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0009319
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002583
- MeSH unique ID (MeSH (Medical Subject Headings))
- D003092